Premium
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma
Author(s) -
Castillo Jorge J.,
GuerreroGarcia Thomas,
Baldini Francesco,
Tcherog Emmanuelle,
Cartron Guillaume,
Ninkovic Slavisa,
Cwynarski Kate,
Dierickx Daan,
Tousseyn Thomas,
Lansigan Frederick,
Linnik Yevgeny,
Mogollon Renzo,
Navarro JoseTomás,
Olszewski Adam J.,
Reagan John L.,
Fedele Pasquale,
Gilbertson Michael,
Grigoriadis George,
Bibas Michele
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15156
Subject(s) - plasmablastic lymphoma , medicine , vincristine , bortezomib , lymphoma , oncology , aggressive lymphoma , rituximab , epoch (astronomy) , etoposide , cyclophosphamide , chemotherapy , multiple myeloma , stars , physics , astronomy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom